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Background: Allergy is a serious problem affecting approximately
1 of 4 individuals. The symptoms with and without allergy etiology
are often difficult to distinguish from each other without using an
IgE antibody test. The aim of this study was to investigate the
performance of a new point-of-care (POC) test for IgE antibodies to
relevant allergens in Europe.
Methods: IgE antibodies from children and adults with allergies
recruited from allergy clinics in Sweden and Spain were analyzed
for 10 allergens, suitable for the age groups, using the new POC test
and ImmunoCAP laboratory test. The IgE antibody level best
discriminating between positive and negative results (the cutoff
point) for the different allergens of the POC test and the efficacy of
the POC and the ImmunoCAP laboratory tests for diagnosing
allergy compared with that of clinical diagnosis were investigated.
Results: The estimated cutoffs for the different allergens in the POC
test ranged from 0.70 to 2.56 kUA/L. Taking into account all positive
allergen results in a given patient, the POC test could identify 95%
of the patients with allergies. Seventy-eight percent of the allergen-
specific physicians’ diagnoses were identified and 97% of the
negative ones. Most allergens exhibited good performance, identi-
fying about 80% of clinically relevant cases. However, dog, mug-
wort, and wall pellitory would benefit from improvement.
Conclusions: The POC test will be a valuable adjunct in the identifi-
cation or exclusion of patients with allergies and their most likely
offending allergens, both in specialist and general care settings.
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The prevalence of allergic diseases has been increasingduring the past several decades, both in the Western world
and in developing countries where a more “Westernized”
lifestyle has been blamed.1–3 The diagnosis of allergic dis-
eases demands confirmation of specific IgE antibodies in
patients with symptoms. This has traditionally been done
using skin prick tests (SPT) that give immediate results, but
are difficult to standardize for inexperienced users. Specific
IgE antibodies have also been demonstrated for more than 30
years in the blood by using fairly advanced and time-con-
suming laboratory tests.4 Thus, there is a need for a well-
standardized, simple, and quick point-of-care (POC) test that
can be easily performed in the physician’s office. The fol-
lowing 4 reasons why a POC test for specific IgE is needed
were identified. First, allergy may affect one fourth of the
population in the Western world.1,2 These patients are seen by
both allergists, who have good experience in allergy diagno-
sis, and by pediatricians and family physicians who have less
experience in this field.
Second, only 1 to 2 of 3 patients suffering from such
symptoms may actually be allergic.5,6 It is frequently difficult
to distinguish between the symptoms of an allergic explana-
tion from a nonallergic one (wheezing, shortness of breath,
dyspnea, bronchi, cough, and chest tightness; nasal conges-
tion, sneezing, rhinorrhea, itching of nose, ears, and eyes, and
postnasal drainage; nausea, vomiting, reflux, constipation, ab-
dominal cramping, and diarrhea; itchy, erythematous, and scaly
skin). The identification of allergy in patients is considerably
hampered without access to an IgE antibody test.7–11
Third, there is a consensus that knowledge of the
allergic status and understanding of the environmental con-
text of a patient will allow a more adequate choice of therapy
and efficient management of the symptoms and evolving
disease.12,13 Likewise, it is important to be able to exclude
allergy from other reasons for the symptoms. In particular, the
presence of allergy and elevated IgE antibody levels represents
a risk for acute and complicating reactions over time.14
Fourth, even if there are hundreds of substances that
can be allergenic, practical clinical experience demonstrates
that a limited number of the most common allergens in the
environment will identify more than 90% of the individuals
with allergies.15
The most effective clinical tool should be simple enough
to be used in the physician’s office and possess the ability to
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verify or exclude the presence of allergy. In addition, this tool
should also not be confused with low-grade sensitization that
can be difficult to interpret,4,14,16–18 even in combination with
case history and physical examination.7,10,11,14,19
We report on the evaluation of a safe and simple tool
for POC testing of relevant IgE antibodies to environmental
allergens in Europe that gives results in a few minutes.
Whereas Diaz-Vazquez et al and Eigenmann et al20,21
evaluated this POC exclusively in children, this study also
addressed adults with similar symptoms.
MATERIALS AND METHODS
Patients
This one-visit multicenter study involved 229 patients
at 7 allergy centers. In Sweden, 3 centers were pediatric
clinics and 1 center an adult clinic. In Spain, 2 centers were
pediatric clinics and 1 was an adult clinic. Patients with a
history of symptoms and sensitization to 1 or more of the
allergens to be evaluated were invited to participate in the
study. Patients between 0 and 18 years of age were recruited
in the pediatric clinics and patients between 19 and 65 years
of age in the adult clinics. For inclusion, the patient needed to
have ongoing symptoms of wheeze/asthma and/or rhinitis.
Also, the patient had to agree to have a 110-L capillary and
a 4-mL venous blood sample taken and to accept participation
by signing an informed consent form. Subjects infected with
HIV and those with a history of hepatitis were excluded from
the study. Case history of allergy-like symptoms and poten-
tial factors giving the patients symptoms of allergy were
recorded. The distribution of patients by demographic char-
acteristics and participating country was similar for both
pediatric and adult clinics and can be provided by the authors
upon request. In the 2 adult clinics, there was a predominance
of females, particularly in Sweden. The adult patients in
Spain were somewhat younger, median 26 years compared
with 36 years in Sweden.
The protocol for this study was reviewed and ap-
proved by the following: Comite Etico Investigacion
Clinica Hospital “Reina Sofia”, Cordoba, Spain; Comite
Etico Investigacion Clinica Hospital Universitario La Fe,
Valencia, Spain; Comite Etico Investigacion Clinica Hospital
Universitario Salamanca, Spain; Forskningsetikkommitte´n
vid Karolinska Institutet, Stockhlm, Sweden; and Forskning-
setikkommitte´n vid Go¨teborgs Universitet, Gothenburg, Swe-
den. Patient informed-consent forms were signed by all
patients—parents and children (age permitting) and adults—
before enrollment.
Point-of-Care Test
Specific IgE antibodies for a total of 10 allergens were
qualitatively determined using 2 test profiles representative of
the regions from where the patients were recruited: 1 for
children (ImmunoCAP Rapid Wheeze-Rhinitis Child) and 1
for adults (ImmunoCAP Rapid Asthma/Rhinitis Adult) (Pha-
dia AB, Uppsala, Sweden). Each profile included 2 control
areas and 10 allergens identifiable on an individualized basis.
For the 2 profiles there were 8 common and 2 profile-specific
allergens. The common allergens were timothy (Phleum prat-
ense), birch (Betula verrucosa), olive (Olea europaea), wall
pellitory (Parietaria judaica), mugwort (Artemisia vulgaris),
cat dander, dog dander, and house dust mite (Dermatopha-
goides pteronyssinus). The 2 profile-specific allergens for the
child test were egg white and milk and, for the adult test,
Alternaria alternata and cockroach (Blatella germanica).
The compositions of the profiles were based on the most
frequent specific allergens known to occur (in Europe) in the
2 target populations: children and adults with allergy-related
symptoms. The allergen reagents on the POC test included
natural extracts and purified allergen components and recom-
binant allergens. To achieve an optimal allergen preparation,
a combination of purified original extract spiked with critical
allergen components was often necessary. Examples of prep-
arations where an increased sensitivity without a decrease in
specificity could be achieved were for olive pollen, where the
original extract was spiked with purified Ole e 1 (a major
component in olive pollen) and for dog spiked with recom-
binant Can f 1 and Can f 2 (major components in dog
epithelia).
At each center, the POC test was performed by an
appointed study nurse and the results remained blind for the
physician until the end of the study. The total time for
running the POC test was 20 minutes after 110 L of blood
was applied to the assay device. Plasma separated from blood
cells by capillary force and flowed onto the 2 parallel visible
test strips. If present, specific IgE antibodies bound to the
zone on the test strip containing the corresponding allergen.
After 5 minutes, a developer solution was added into a
separate well, releasing a dried gold conjugate that similarly
flowed onto the test trips. After an additional 15 minutes, the
conjugate formed a visible pink-red complex with any bound
IgE antibodies for a positive allergen in the test strip. A
invisible line was read as negative, indicating that specific
IgE antibodies were undetectable with this POC test. Two
control windows, one on each strip, indicated whether the test
run should be approved or not. The principle of the test has
also been published elsewhere.20,22
Reproducibility studies performed by the manufacturer
have shown the same response (positive or negative) in 94%
of the tests when repeated on different occasions and across
different batches. High levels of total IgE, up to 3000 kU/L,
did not interfere with the test results. Similarly, no measur-
able cross-reactivity was observed of the IgE-specific conju-
gate with human IgG, IgA, IgD, or IgM and no interference
from hemoglobin, bilirubin, triglycerides, or cholesterol was
detected within normal concentration ranges. Test results
were not affected by hematocrit levels up to 48%.22
Quantitative Allergen-Specific IgE
Measurements
For all patients the quantitative specific IgE antibody
level was determined for each allergen included in the new
tests by using the venous blood sample (ImmunoCAP, Phadia
AB, Uppsala, Sweden). A patient with IgE antibody levels
above 0.35 kUA/L to an individual allergen was considered
sensitized.
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Clinical Evaluation of the POC Test
Each patient was examined separately for each of the
10 allergens where each allergen was classified as “positive”,
“negative”, or “inconclusive”. At each center, there was 1
physician responsible for the clinical judgment of the partic-
ipating patients. The physician’s judgment was based on,
besides case history and physical examination, SPT results
(SPT cutoff point: wheal diameter 3mm) and/or Immuno-
CAP specific IgE determinations (cutoff point:0.35 kUA/L)
when necessary. An inconclusive diagnosis was set when
case history and the laboratory IgE test result or any previous
test result did not correspond.
For the evaluation of the diagnostic performance of
the POC test, the results for each allergen were compared
with the positive and negative classifications made by the
physicians.
Data Analysis and Statistical Methods
The percentage agreement of a positive POC test with
the physician’s positive diagnosis and the percentage agree-
ment of a negative POC test with the physician’s negative
diagnosis were calculated for each separate allergen and for
all allergens collectively.
For each allergen, receiver-operating characteristic
(ROC) analysis23 was used in a reversed manner to estimate
cutoff levels for the quantitative laboratory test, using the
results of the POC test as the reference, that is, to estimate
specific IgE levels that best discriminated between positive
and negative results of the POC test. This was done using all
available observations, irrespective of allergen diagnosis.
On the basis of the physician’s positive or negative
classification, the clinical performance of the POC test was
compared with the performance of the ImmunoCAP Specific
IgE using both the standard cutoff and the cutoff estimated
from the data.
Statistical analyses were performed using the SAS
statistical software system (v8.2). Microsoft Excel 2003 was
used for figures and plots.
RESULTS
Overall, in the pediatric clinics, 73 children (60%)
presented with a diagnosis of asthma and 101 children (84%)
with rhinitis. The prevalence of asthma and allergic rhinitis in
Swedish children was 90% for each, whereas that in the
children from Spain was 24% for asthma and 76% for
rhinitis. In the adult clinics, a similar number of patients were
seen in the 2 countries with 90% symptoms for rhinitis and
64% for asthma. In the pediatric clinics, the most common
self-reported allergens were tree pollen (55%), cat dander
(50%), and grass pollen (49%). Infection headed the list of
nonallergen triggering factors (49%). The percentage of each
triggering factor was generally higher in Sweden than in
Spain. In the adult clinics, the most common allergens re-
ported were tree pollen (75%), house dust mite (62%), and cat
dander (46%). Nonallergen triggering factors, such as smok-
ing (57%), infection (51%), and exercise (48%), were similar
in both countries.
Estimated Cutoffs per Allergen for the POC
Test Calculated Using the Quantitative
Laboratory Blood Test
The cutoff for each allergen of the new POC test was
calculated with the laboratory test by estimating the kUA/L
levels giving the best discrimination between positive and
negative POC test results. Different levels were found for the
different allergens, ranging from a low of 0.70 kUA/L for
milk to a high of 2.56 kUA/L for wall pellitory (Table 1). This
gave a percentage agreement between the laboratory test
results with the positive and negative POC test results ranging
from 92% and 94% respectively for milk to 77% and 95%
respectively for wall pellitory, with all other allergens falling
in between.
Performance of the POC Test and the Laboratory
Test Compared with the Physician’s Diagnosis
In total, 218 of the 229 patients tested positive to at
least 1 allergen in the POC test. Of these patients, 216 had at




















House dust mite 0.82 80 82 99 95 117 93 93 97
Cat 0.72 98 81 96 87 101 98 97 100
Dog 1.81 74 51 97 68 103 100 79 99
Timothy grass 2.42 125 82 98 84 67 97 94 100
Birch 2.15 81 90 100 89 93 95 82 100
Olive 1.41 63 81 100 84 86 100 86 99
Mugwort 1.27 32 53 94 72 128 95 88 98
Wall pellitory 2.56 17 82 100 71 133 97 84 99
Egg white 0.90 32 84 94 84 86 97 98 99
Cow’s milk 0.70 25 84 100 92 89 98 94 99
A. alternata 2.33 24 88 96 92 74 97 97 100
Cockroach — 2 50 100 — 87 99 97 —
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least 1 positive allergen diagnosis made by the physician. In
addition, 9 of the 11 subjects with negative POC test had at
least 1 such positive allergen diagnosis made by the physi-
cian. Thus, of the 225 patients with at least 1 positive clinical
allergen diagnosis, the POC test recognized 216 or 95% of
them.
In total, 2284 allergen-specific diagnoses were made in
the 229 patients. The number of positive and negative diag-
noses were 653 and 1165, respectively. The number of
inconclusive diagnoses was 466. For each single allergen the
distribution of the POC test results versus the physicians’
positive and negative diagnoses is shown in Table 1. In total,
78% of the physicians’ positive allergen diagnoses were
associated with a positive result in the POC test. In the case of
the physicians’ negative allergen diagnoses, the POC test results
were negative in 97% of the cases. This resulted in an overall
agreement of the study test compared with the positive and
negative diagnoses of 90%. The results from children and adults
were comparable (Fig. 1) as were those from Spain and Sweden
(not shown), justifying analysis as a single group.
The performance of the POC test compared with that of
the laboratory test using the clinical diagnosis as the discrim-
inator is shown in Figure 1 and Table 1. The agreement of a
positive POC test result and a laboratory test result above the
cutoff value, as estimated for the individual allergens in the
POC test with a clinical diagnosis, was above 80% for most
allergens (Table 1). However, the concordance of the results
was lower for dog and mugwort. The concordance of positive
POC test results with results of positive clinical diagnosis was
compared with the concordance of positive specific IgE
results from the laboratory test using the ordinary 0.35 kUA/L
cutoff for the individual allergens with results of positive
clinical diagnosis. It was found that the performance of the
POC test was about 15% lower, with the exception of dog and
mugwort where the differences were 46% and 41% lower,
respectively (Table 1).
The corresponding analysis of the agreement of nega-
tive POC test results with negative clinical diagnosis showed
concordant results, with values well above 90% and, for
many allergens, close to 100% when compared with the
laboratory test (Table 1). As expected, when compared with
the regular 0.35kUA/L cutoff, most allergens showed better
agreement with the physician’s diagnosis in the POC test,
albeit in most instances less than 15% than for the laboratory
ImmunoCAP test. The exception was for dog where there
was a 21% better outcome in the POC test. In all these
analyses the results were very similar for both children and
adults (Fig. 1) and both Spain and Sweden (not shown).
In the recruited patients, the number of inconclusive
clinical classifications per allergen was, in total, 466 (20%),
that is, discordant results between clinical history and labo-
ratory IgE antibody test, or any previous test results. Of these
results, 30% were positive in the POC test. One of the most
difficult allergens to diagnose in this study, resulting in
inconclusive diagnosis, was wall pellitory in both countries
(31% in Spain and 18% in Sweden). Likewise, inconclusive
diagnosis was high for birch in Spain (34%) and for olive tree
in Sweden (25%).
DISCUSSION
The POC test was able to identify 95% of the patients
having a diagnosis of allergic disease. Despite this excellent
result this new test exhibited somewhat lower sensitivity than
the conventional laboratory test ImmunoCAP.24 It could cor-
rectly identify 78% of the allergen-specific diagnoses and
97% of the negative allergen-specific diagnoses, giving an
overall concordance of 90%. These results are in accordance
with the results obtained in previous studies using the POC
test.20,21 However, in this study it was found that the results
between the specific allergens varied within a wide range;
that is, the range in sensitivity was from around 50% for dog,
mugwort, and cockroach to around 90% for A. alternata and
birch. Concerning the relatively low values for the allergens
for dog, mugwort, and cockroach, they would probably ben-
efit from a manufacturer’s test improvement.
To increase the prevalence of clinical allergy and sen-
sitization to the employed allergens, it was decided to include
patients previously recognized as having allergies. This ap-
proach enriched the population of people with allergies com-
pared with a consecutive enrollment but still allowed analysis
of clinical and serological reactivity to both offending and
nonoffending allergens. Therefore, it was not surprising that
218 patients of 229 were positive in the POC test to 1 or more
of the employed allergens and 225 patients had a positive
general allergy diagnosis. In an attempt to cover different
regions of exposure, patients from both Spain and Sweden
were included, consisting of both adults and children. There
was no indication that the inclusion of patients from northern
and southern Europe and of different ages blurred the results.
Individual allergen results showed that there was a difference
in the number of inconclusive results in patients for birch
pollen in Spain and for olive and wall pellitory in Sweden.
This may be due to the fact that these pollens do not occur in
the respective region and the results may be due to cross-
reactivity between allergens. For example, ash (Fraxinus),
lilac (Syringa), and privet (Ligustrum) are trees present in the
northern European region and belong to the same family
(Oleaceae) as olive (Olea). As such, these results may be
considered as irrelevant.
In the present study there was a positive or negative
diagnosis for the majority of the individual allergens in the
recruited patients. However, there were also those with in-
conclusive diagnoses. Many of those cases exhibited low IgE
antibody levels to the allergens (unpublished results). This
finding may be taken as proof of the difficulty to link
low-grade sensitization and low IgE antibody levels with
actual clinical symptoms.
The POC test exhibited somewhat lower sensitivity
than the laboratory test. Therefore, the cutoffs for the differ-
ent allergens in the POC test were estimated and interpreted
in relation to the laboratory test using a reversed ROC
method. Normally, ROC analysis could be used to select a
cutoff for a quantitative test versus a qualitative (positive or
negative) reference. In this study, however, the laboratory test
was used as the quantitative test and the test in question, the
POC test, as the qualitative reference. The estimation of the
cutoff could thus be performed to provide the best agreement
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with the laboratory test ImmunoCAP Specific IgE. Many
individuals may have detectable IgE antibodies without hav-
ing any symptoms at the given moment. This is seen in both
small children25 and adults26 who become sensitized before
symptoms evolve. Furthermore, in food allergy, probability
curves have been developed to find a better association
between clinical reactivity and IgE antibody levels higher
than the generally accepted cutoff level of 0.35 kUA/L.27–30
Similarly, in respiratory allergy, elevated IgE antibody levels
have been shown to be more closely associated with current
symptoms10,14,18,19 and decreased lung function18 than lower
IgE antibody levels. This pattern is also accentuated in
determining the risk for acute asthma exacerbations.14 After
this, one can speculate that the use of a test with a higher
FIGURE 1. Percentage agreement of the POC test results with the physician’s diagnosis for (A) children and (B) adults.
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cutoff will probably identify patients with a higher likelihood
of allergy problems and could therefore be appropriate as a
first-line diagnostic tool, especially if used in settings with
patients presenting with a lower prevalence of allergy. Fur-
thermore, it can be seen in the literature that different authors
choose cutoffs above 0.35 kUA/L in their clinical practical
use of IgE antibody testing.31
There was a concern that patients seen by a specialist
are generally more heavily sensitized with higher IgE anti-
body levels than patients seen by primary care physicians.
This may lower the usefulness of a less sensitive test such as
the POC test compared with the regular laboratory test.
However, with re-analysis of previously published data from
primary care in Italy and Spain9 and in allergist clinics in Italy,
Germany, The Netherlands, and England,32 we were able to
confirm that this was not the case (unpublished results).
CONCLUSIONS
In conclusion, this study revealed that this POC test for
IgE antibodies has a high capability of identifying patients
with allergic etiology for their symptoms, despite somewhat
higher cutoffs for the different allergens employed than those
currently used in laboratory tests.
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